Antigen presentation in graft-vs-host disease

Experimental Hematology

Volumn 31, Issue 12, 2003, Pages 1187-1197

  Shlomchik, Warren D ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; B7 ANTIGEN; CD134 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; LYMPHOCYTE ANTIGEN RECEPTOR; LYMPHOTOXIN BETA RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIGHT; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELL DEATH; CELL INTERACTION; CELL MATURATION; CHIMERA; CYTOKINE PRODUCTION; DENDRITIC CELL; DONOR; GRAFT VERSUS HOST REACTION; HOST; HOST PATHOGEN INTERACTION; HUMAN; INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0345528840     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2003.09.017     Document Type: Review

References (137)

1. Lucarelli G., Clift R.A., Galimberti M., et al. Bone marrow transplantation in adult thalassemic patients. Blood. 93:1999;1164-1167.
2. Lucarelli G., Galimberti M., Giardini C., et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci. 850:1998;270-275.
3. Boulad F., Giardina P., Gillio A., et al. Bone marrow transplantation for homozygous beta-thalassemia. The Memorial Sloan-Kettering Cancer Center experience. Ann N Y Acad Sci. 850:1998;498-502.
4. Walters M.C., Patience M., Leisenring W., et al. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. Biol Blood Marrow Transplant. 3:1997;310-315.
5. Gaziev D., Polchi P., Galimberti M., et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation. 63:1997;854-860.
6. Walters M.C., Patience M., Leisenring W., et al. Bone marrow transplantation for sickle cell disease. [see comments] N Engl J Med. 335:1996;369-376.
7. Reis e Sousa C. Dendritic cells as sensors of infection. Immunity. 14:2001;495-498.
8. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
9. Wolf P.R., Ploegh H.L. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol. 11:1995;267-306.
10. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr Opin Immunol. 8:1996;348-354.
11. Sant A.J. Endogenous antigen presentation by MHC class II molecules. Immunol Res. 13:1994;253-267.
12. Germain R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. [Review] Cell. 76:1994;287-299.
13. Steinman R.M., Inaba K., Turley S., Pierre P., Mellman I. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol. 60:1999;562-567.
14. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta. 1589:2002;1-13.
15. Janeway C.A. Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol. 20:2002;197-216.
16. Ackerman A.L., Cresswell P. Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. J Immunol. 170:2003;4178-4188.
17. Chow A., Toomre D., Garrett W., Mellman I. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature. 418:2002;988-994.
18. Turley S.J., Inaba K., Garrett W.S., et al. Transport of peptide-MHC class II complexes in developing dendritic cells. Science. 288:2000;522-527.
19. Medzhitov R., Janeway C.A. Jr. How does the immune system distinguish self from nonself? Semin Immunol. 12:2000;185-188. discussion 257-344.
20. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol. 21:2003;685-711.
21. + T cell tolerance. J Exp Med. 196:2002;1627-1638.
22. Liu K., Iyoda T., Saternus M., Kimura Y., Inaba K., Steinman R.M. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med. 196:2002;1091-1097.
23. Steinman R.M., Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A. 99:2002;351-358.
24. Hawiger D., Inaba K., Dorsett Y., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 194:2001;769-779.
25. + T cell tolerance. Immunity. 18:2003;713-720.
26. Wakkach A., Fournier N., Brun V., Breittmayer J.P., Cottrez F., Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 18:2003;605-617.
27. Martin E., O'Sullivan B., Low P., Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity. 18:2003;155-167.
28. Wilson N.S., El-Sukkari D., Belz G.T., et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood. 2003;. In press.
29. Miller G., Pillarisetty V.G., Shah A.B., Lahrs S., DeMatteo R.P. Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties. J Immunol. 170:2003;3554-3564.
30. Sato K., Yamashita N., Baba M., Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood. 101:2003;3581-3589.
31. Sato K., Yamashita N., Baba M., Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity. 18:2003;367-379.
32. Sherman L.A., Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol. 11:1993;385-402.
33. Ronchese F., Brown M.A., Germain R.N. Structure-function analysis of the Abm12 beta mutation using site-directed mutagenesis and DNA-mediated gene transfer. J Immunol. 139:1987;629-638.
34. Melief C.J., de Waal L.P., van der Meulen M.P., Melvold R.W., Kohn H.I. Fine specificity of alloimmune cytotoxic T lymphocytes directed against H-2K. A study with Kb mutants. J Exp Med. 151:1980;993-1013.
35. Korngold R., Sprent J. T-cell subsets and graft-vs-host disease. Burakoff S.J., Deeg H.J., Ferrara J., Atkinson K. Graft-vs.-Host Disease. 1990;31-50 Marcel Dekker, Inc, New York.
36. Sprent J., Miller J.F., Mitchell G.F. Antigen-induced selective recruitment of circulating lymphocytes. Cell Immunol. 2:1971;171-181.
37. Sprent J., Schaefer M., Lo D., Korngold R. Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med. 163:1986;998-1011.
38. + T cells by semiprofessional antigen-presenting cells in vivo. J Exp Med. 176:1992;1291-1302.
39. Gao E.K., Kosaka H., Surh C.D., Sprent J. T cell contact with Ia antigens on nonhemopoietic cells in vivo can lead to immunity rather than tolerance. J Exp Med. 174:1991;435-446.
40. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 295:2002;2097-2100.
41. German R.N., Castellino F., Han R., et al. Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. Immunol Rev. 151:1996;5-30.
42. Moore M.W., Carbone F.R., Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54:1988;777-785.
43. Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 143:1976;1283-1288.
44. Matzinger P., Bevan M.J. Induction of H-2-restricted cytotoxic T cells: in vivo induction has the appearance of being unrestricted. Cell Immunol. 33:1977;92-100.
45. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965.
46. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 269:1995;1585-1588.
47. Kurts C., Miller J.F., Subramaniam R.M., Carbone F.R., Heath W.R. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med. 188:1998;409-414.
48. Korngold R., Sprent J. Negative selection of T cells causing lethal graft-versus-host disease across minor histocompatibility barriers. Role of the H-2 complex. J Exp Med. 151:1980;1114-1124.
49. Korngold R., Sprent J. Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med. 155:1982;872-883.
50. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen- presenting cells. Science. 285:1999;412-415.
51. + T cells. Science. 248:1990;1227-1230.
52. + T cell- mediated acute graft-versus-host disease. J Clin Invest. 109:2002;1335-1344.
53. Shlomchik W.D., Cormier J., Matte C., Anderson B.E., Shlomchik M.J. Donor derived antigen presenting cells are not required for CD8 T cell induced GVHD. Blood. 100:2002;820.
54. Gett A.V., Sallusto F., Lanzavecchia A., Geginat J. T cell fitness determined by signal strength. Nat Immunol. 4:2003;355-360.
55. + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol. 2:2001;415-422.
56. van Stipdonk M.J., Lemmens E.E., Schoenberger S.P. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol. 2:2001;423-429.
57. Van Stipdonk M.J., Hardenberg G., Bijker M.S., et al. Dynamic programming of CD8(+) T lymphocyte responses. Nat Immunol. 4:2003;361-365.
58. Bogen B., Weiss S. Processing and presentation of idiotypes to MHC-restricted T cells. Int Rev Immunol. 10:1993;337-355.
59. Brooks A.G., McCluskey J. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen presenting cells. J Immunol. 150:1993;3690-3697.
60. Bodmer H., Viville S., Benoist C., Mathis D. 1994. Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science. 263:1994;1284-1286.
61. Lechler R., Aichinger G., Lightstone L. The endogenous pathway of MHC class II antigen presentation. Immunological Reviews. 151:1996;51-79.
62. Hamilton B.L. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol. 139:1987;2511-2515.
63. Zhang Y., McCormick L.L., Desai S.R., Wu C., Gilliam A.C. 2002. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 168:2002;3088-3098.
64. McCormick L.L., Zhang Y., Tootell E., Gilliam A.C. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 163:1999;5693-5699.
65. Anderson B.E., Shlomchik W., Shlomchik M. Mechanisms of chronic graft-vs-host disease induction and pathogenesis in an MHC-matched MiHA-incompatible murine model. [abstract] Blood. 2001;98. Abstract 2727.
66. + T cells do not induce graft-versus-host disease. J Clin Invest. 112:2003;101-108.
67. Medzhitov R., Janeway C. Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev. 173:2000;89-97.
68. Shlomchik W.D., Cormier J., Matte C., Anderson B.E., Shlomchik M.J. Costimulation, activation and maturation of host APCs during GVHD. Blood. 100:2002;820.
69. Krenger W., Hill G.R., Ferrara J.L. Cytokine cascades in acute graft-versus-host disease. Transplantation. 64:1997;553-558.
70. McCarthy P.L. Jr., Abhyankar S., Neben S., et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood. 78:1991;1915-1918.
71. Cooke K.R., Hill G.R., Crawford J.M., et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 102:1998;1882-1891.
72. Hill G.R., Teshima T., Rebel V.I., et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol. 164:2000;656-663.
73. Cooke K.R., Gerbitz A., Crawford J.M., et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. [comment] J Clin Invest. 107:2001;1581-1589.
74. Kaisho T., Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol. 22:2001;78-83.
75. Carreno B.M., Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 20:2002;29-53.
76. Greenwald R.J., Latchman Y.E., Sharpe A.H. Negative co-receptors on lymphocytes. Curr Opin Immunol. 14:2002;391-396.
77. Liang L., Sha W.C. The right place at the right time: novel B7 family members regulate effector T cell responses. Curr Opin Immunol. 14:2002;384-390.
78. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nature Reviews. Immunology. 2:2002;116-126.
79. Toes R.E., Schoenberger S.P., van der Voort E.I., Offringa R., Melief C.J. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Sem Immunol. 10:1998;443-448.
80. Okazaki T., Iwai Y., Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol. 14:2002;779-782.
81. Mackay F., Kalled S.L. TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol. 14:2002;783-790.
82. Yu X.Z., Martin P.J., Anasetti C. Role of CD28 in acute graft-versus-host disease. Blood. 92:1998;2963-2970.
83. Blazar B.R., Taylor P.A., Panoskaltsis-Mortari A., Sharpe A.H., Vallera D.A. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol. 162:1999;6368-6377.
84. Speiser D.E., Bachmann M.F., Shahinian A., Mak T.W., Ohashi P.S. Acute graft-versus-host disease without costimulation via CD28. Transplantation. 63:1997;1042-1044.
85. Blazar B.R., Taylor P.A., Linsley P.S., Vallera D.A. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood. 83:1994;3815-3825.
86. Blazar B.R., Taylor P.A., Gray G.S., Vallera D.A. The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibility-disparate donor inocula. Transplantation. 58:1994;1422-1426.
87. Via C.S., Rus V., Nguyen P., Linsley P., Gause W.C. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol. 157:1996;4258-4267.
88. + T cells. J Immunol. 157:1996;3250-3259.
89. Kundig T.M., Shahinian A., Kawai K., et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity. 5:1996;41-52.
90. Shahinian A., Pfeffer K., Lee K.P., et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science. 261:1993;609-612.
91. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 16:1998;111-135.
92. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:1998;480-483.
93. + T-helper and a T-killer cell. [see comments] Nature. 393:1998;474-478.
94. Durie F.H., Aruffo A., Ledbetter J., et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest. 94:1994;1333-1338.
95. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 158:1997;29-39.
96. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 186:1997;47-55.
97. Goodwin R.G., Din W.S., Davis-Smith T., et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol. 23:1993;2631-2641.
98. Blazar B.R., Kwon B.S., Panoskaltsis-Mortari A., Kwak K.B., Peschon J.J., Taylor P.A. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft- versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol. 166:2001;3174-3183.
99. Chen A.I., McAdam A.J., Buhlmann J.E., et al. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity. 11:1999;689-698.
100. Ohshima Y., Tanaka Y., Tozawa H., Takahashi Y., Maliszewski C., Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 159:1997;3838-3848.
101. Murata K., Ishii N., Takano H., et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med. 191:2000;365-374.
102. Tsukada N., Akiba H., Kobata T., Aizawa Y., Yagita H., Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood. 95:2000;2434-2439.
103. Yoshinaga S.K., Whoriskey J.S., Khare S.D., et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature. 402:1999;827-832.
104. Tafuri A., Shahinian A., Bladt F., et al. ICOS is essential for effective T-helper-cell responses. Nature. 409:2001;105-109.
105. Dong C., Juedes A.E., Temann U.A., et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 409:2001;97-101.
106. Ogawa S., Nagamatsu G., Watanabe M., et al. Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease. J Immunol. 167:2001;5741-5748.
107. Mauri D.N., Ebner R., Montgomery R.I., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity. 8:1998;21-30.
108. Tamada K., Shimozaki K., Chapoval A.I., et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol. 164:2000;4105-4110.
109. Granger S.W., Rickert S. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. Cytokine Growth Factor Rev. 14:2003;289-296.
110. + T cell function in mice lacking the TNF superfamily member LIGHT. J Immunol. 168:2002;4832-4835.
111. Shi G., Luo H., Wan X., Salcedo T.W., Zhang J., Wu J. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood. 100:2002;3279-3286.
112. Scheu S., Alferink J., Potzel T., Barchet W., Kalinke U., Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med. 195:2002;1613-1624.
113. Harrop J.A., McDonnell P.C., Brigham-Burke M., et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem. 273:1998;27548-27556.
114. Tamada K., Shimozaki K., Chapoval A.I., et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med. 6:2000;283-289.
115. Tamada K., Tamura H., Flies D., et al. Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest. 109:2002;549-557.
116. Maraskovsky E., Brasel K., Teepe M., et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 184:1996;1953-1962.
117. Viney J.L., Mowat A.M., O'Malley J.M., Williamson E., Fanger N.A. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol. 160:1998;5815-5825.
118. Pulendran B., Smith J.L., Jenkins M., Schoenborn M., Maraskovsky E., Maliszewski C.R. Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J Exp Med. 188:1998;2075-2082.
119. Williamson E., Westrich G.M., Viney J.L. Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol. 163:1999;3668-3675.
120. Teshima T., Reddy P., Lowler K.P., et al. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease. Blood. 99:2002;1825-1832.
121. Blazar B.R., McKenna H.J., Panoskaltsis-Mortari A., Taylor P.A. Flt3 ligand (FL) treatment of murine donors does not modify graft- versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality. Biol Blood Marrow Transplant. 7:2001;197-207.
122. Yunusov M.Y., Georges G.E., Storb R., et al. FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease. Transplantation. 75:2003;933-940.
123. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 344:2001;175-181.
124. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 95:2002;3702-3709.
125. Blaise D., Kuentz M., Fortanier C., et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 18:2000;537-546.
126. Couban S., Simpson D.R., Barnett M.J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 100:2002;1525-1531.
127. Arpinati M., Green C.L., Heimfeld S., Heuser J.E., Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. [see comments] Blood. 95:2000;2484-2490.
128. Waller E.K., Rosenthal H., Jones T.W., et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood. 97:2001;2948-2956.
129. Pan L., Delmonte J. Jr., Jalonen C.K., Ferrara J.L. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 86:1995;4422-4429.
130. Pan L., Teshima T., Hill G.R., et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood. 93:1999;4071-4078.
131. Walker L.S., Abbas A.K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol. 2:2002;11-19.
132. + T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med. 188:1998;415-420.
133. Steinman R.M., Turley S., Mellman I., Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 191:2000;411-416.
134. Lanzavecchia A., Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol. 13:2001;291-298.
135. Cohen J.L., Trenado A., Vasey D., Klatzmann D., Salomon B.L. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft- versus-host disease. J Exp Med. 196:2002;401-406.
136. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) Regulatory T Cells Suppress Lethal Acute Graft- Versus-Host Disease after Allogeneic Bone Marrow Transplantation. J Exp Med. 196:2002;389-399.
137. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 99:2002;3493-3499.